During the past decade, Ludwig Institute for Cancer Research conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Ludwig Institute for Cancer Research" are "Malignant Melanoma" (2 trials) and "Unspecified Adult Solid Tumor, Protocol Specific" (2 trials). Many other conditions were trialed in "Ludwig Institute for Cancer Research" in a lesser frequency.

Most popular intervention types in "Ludwig Institute for Cancer Research" are "Biological" (2 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "8 HLA-A2-restricted peptides and CpG 7909" (1 trials), "8 HLA-A2-restricted peptides and Montanide ISA51" (1 trials), "CHS 828" (1 trials), "MAGE-3.A1 peptide and CpG 7909" (1 trials) and "indisulam" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ludwig Institute for Cancer Research" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Ludwig Institute for Cancer Research". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Ludwig Institute for Cancer Research, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ludwig Institute for Cancer Research, 4 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".